Aucubin can also alleviate nonalcoholic fatty liver disease (NAFLD) caused by obesity [62] through several mechanisms: inhibiting the release of proinflammatory cytokines (TNF-α, IL-1β, IL-6) and increasing the phosphorylation of ACC, AMPKα, and AKT that stimulate more production of antioxidant enzymes. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.